Red Biotechnology Market – Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, 2018-2028 Segmented By Product Type (Diagnostic Reagents, Human Vaccines, Blood Products, Gene Recombinant Drugs and Others), By Application (Biopharmaceutical Production, Gene Therapy, Genetic Testing, Pharmacogenomics, Drug Discovery and Others), By End-User (Pharmaceutical and Biotechnology Companies, CMO & CRO, Research Institute and Others), By Region
Global Red Biotechnology Market is expected to grow with an impressive CAGR in the forecast period of 2024-2028. This can be attributed to factors such as the growing demand for genetic engineering, the development of new medicines for the treatment of life-threatening diseases, and the increased production of precision medicine.
Red Biotechnology focuses on the therapeutic or diagnostic use of living cells and their components to develop novel medical treatments and cures for diseases and health issues. It includes the creation of a wide range of goods, including medicines, diagnostic instruments, vaccines, gene treatments, and other products for the treatment and prevention of different diseases.
The growing demand for precision medicine is enhancing the market opportunities and increasing demand for the global red biotechnology market.
Growing Demand for Genetic Engineering
An increase in demand for genetic engineering has been observed due to an increase in biologic drugs. According to IQVIA Institute data, biologic drugs represented 2 percent of all United States prescriptions but comprised 37% net drug spending. The growing use of genetic engineering, such as recombinant DNA technology, in creating genetically modified organisms, such as therapeutic antibodies, is propelling the growth of the red biotechnology market across the globe. The technologies, such as gene editing, such as CRISPR-based genetic editing, are also becoming much prevalent in the market and thereby are supporting the market growth by expanding the applications of red biotechnology in genetic engineering. Additionally, red biotechnology is found to have applications in the production of spinal discs, artificial bones, skin, and cartilage through tissue engineering techniques.
Development of new medicines for the treatment of life-threatening diseases
Red biotechnology has found applications in fields such as gene therapy, clinical trials, diagnostics, and research. Also, the growing number of clinical trials for the development of drugs, along with the rise in acceptance and demand for biosimilars, affect the growth of red biotechnology in the recent scenario. The expansion of the biopharmaceutical sector of the red biotechnology market is expected to grow with increasing clinical trials in medicine production. For instance, In July 2022, Replay-a genomic medicine-producing startup, invested USD55 million in a seed funding round to develop and transform genomic medicine through an interlinking stage for developing various genotype genomic research to discover new disease targets and enhance and improve the disease diagnosis & treatment.
Increased production of precision medicine
The growing prevalence of chronic diseases across the world is creating a rising demand for precision medicine. According to the World Health Organization (WHO), cancer is the second leading cause of death globally and has recorded around 9.6 million deaths globally. With the increasing number of cancer patients worldwide, the growth of the red biotechnology market is also expanding as it is utilized for diagnosing the reason for these diseases by using genetic testing and sequencing techniques, etc., and thereby has found many lucrative opportunities in diagnosis, drug development and treatment for diseases such as cancer and is thereby expected to bolster market growth in the forecast period. Along with this, red biotechnology is utilized in combined vaccine production, such as Hepatitis B, merged with the polio vaccine, and DPT merged with Hepatitis A, and this all together is of great importance to support the market growth in the forecast period.
Recent Development
In June 2022, Bluebird Bio developed a new gene therapy that is being evaluated by the United States Food Drug and Administration regarding the treatment of (CALD) cerebral adrenoleukodystrophy (a genetic condition that damages the membrane myelin sheath of the brain) in patients under adolescent age.
Market Segmentation
Global Red Biotechnology Market is segmented based on the product type, application, end-user, region, and competitive landscape. Based on product type, the market is segmented into diagnostic reagents, human vaccines, blood products, gene recombinant drugs, and others. Based on application, the market is segmented into biopharmaceutical production, gene therapy, genetic testing, pharmacogenomics, drug discovery, and others. Based on end-user, the market is segmented into pharmaceutical and biotechnology companies, CMO & CRO, research institutes, and others.
Market Players
Pfizer, Inc., Takeda Pharmaceutical Company Limited, Gilead Sciences, Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche, Ltd., Bruker, Merck KGaA, Celgene Corporation, Amgen, Inc., etc., are some of the major players operating in the Global Red Biotechnology Market.
Report Scope:
In this report, Global Red Biotechnology Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Red Biotechnology Market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
Red Biotechnology focuses on the therapeutic or diagnostic use of living cells and their components to develop novel medical treatments and cures for diseases and health issues. It includes the creation of a wide range of goods, including medicines, diagnostic instruments, vaccines, gene treatments, and other products for the treatment and prevention of different diseases.
The growing demand for precision medicine is enhancing the market opportunities and increasing demand for the global red biotechnology market.
Growing Demand for Genetic Engineering
An increase in demand for genetic engineering has been observed due to an increase in biologic drugs. According to IQVIA Institute data, biologic drugs represented 2 percent of all United States prescriptions but comprised 37% net drug spending. The growing use of genetic engineering, such as recombinant DNA technology, in creating genetically modified organisms, such as therapeutic antibodies, is propelling the growth of the red biotechnology market across the globe. The technologies, such as gene editing, such as CRISPR-based genetic editing, are also becoming much prevalent in the market and thereby are supporting the market growth by expanding the applications of red biotechnology in genetic engineering. Additionally, red biotechnology is found to have applications in the production of spinal discs, artificial bones, skin, and cartilage through tissue engineering techniques.
Development of new medicines for the treatment of life-threatening diseases
Red biotechnology has found applications in fields such as gene therapy, clinical trials, diagnostics, and research. Also, the growing number of clinical trials for the development of drugs, along with the rise in acceptance and demand for biosimilars, affect the growth of red biotechnology in the recent scenario. The expansion of the biopharmaceutical sector of the red biotechnology market is expected to grow with increasing clinical trials in medicine production. For instance, In July 2022, Replay-a genomic medicine-producing startup, invested USD55 million in a seed funding round to develop and transform genomic medicine through an interlinking stage for developing various genotype genomic research to discover new disease targets and enhance and improve the disease diagnosis & treatment.
Increased production of precision medicine
The growing prevalence of chronic diseases across the world is creating a rising demand for precision medicine. According to the World Health Organization (WHO), cancer is the second leading cause of death globally and has recorded around 9.6 million deaths globally. With the increasing number of cancer patients worldwide, the growth of the red biotechnology market is also expanding as it is utilized for diagnosing the reason for these diseases by using genetic testing and sequencing techniques, etc., and thereby has found many lucrative opportunities in diagnosis, drug development and treatment for diseases such as cancer and is thereby expected to bolster market growth in the forecast period. Along with this, red biotechnology is utilized in combined vaccine production, such as Hepatitis B, merged with the polio vaccine, and DPT merged with Hepatitis A, and this all together is of great importance to support the market growth in the forecast period.
Recent Development
In June 2022, Bluebird Bio developed a new gene therapy that is being evaluated by the United States Food Drug and Administration regarding the treatment of (CALD) cerebral adrenoleukodystrophy (a genetic condition that damages the membrane myelin sheath of the brain) in patients under adolescent age.
Market Segmentation
Global Red Biotechnology Market is segmented based on the product type, application, end-user, region, and competitive landscape. Based on product type, the market is segmented into diagnostic reagents, human vaccines, blood products, gene recombinant drugs, and others. Based on application, the market is segmented into biopharmaceutical production, gene therapy, genetic testing, pharmacogenomics, drug discovery, and others. Based on end-user, the market is segmented into pharmaceutical and biotechnology companies, CMO & CRO, research institutes, and others.
Market Players
Pfizer, Inc., Takeda Pharmaceutical Company Limited, Gilead Sciences, Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche, Ltd., Bruker, Merck KGaA, Celgene Corporation, Amgen, Inc., etc., are some of the major players operating in the Global Red Biotechnology Market.
Report Scope:
In this report, Global Red Biotechnology Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:
- Red Biotechnology Market, By Product Type:
- Diagnostic Reagents
- Human Vaccines
- Blood Products
- Gene Recombinant drugs
- Others
- Red Biotechnology Market, By Application:
- Biopharmaceutical Production
- Gene Therapy
- Genetic Testing
- Pharmacogenomics
- Drug Discovery
- Others
- Red Biotechnology Market, By End-User:
- Pharmaceutical and Biotechnology companies
- CMO & CRO
- Research Institute
- Others
- Red Biotechnology Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
- South America
- Brazil
- Argentina
- Colombia
Company Profiles: Detailed analysis of the major companies present in the Global Red Biotechnology Market.
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered.
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. RED BIOTECHNOLOGY MARKET OUTLOOK.
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product Type (Diagnostic Reagents, Human Vaccines, Blood Products, Gene Recombinant Drugs and Others)
5.2.2. By Application (Biopharmaceutical Production, Gene Therapy, Genetic Testing, Pharmacogenomics, Drug Discovery, and Others)
5.2.3. By End-User (Pharmaceutical and Biotechnology companies, CMO & CRO, Research Institute and Others)
5.2.4. By Company (2022)
5.2.5. By Region
5.3. Product Market Map
6. ASIA-PACIFIC RED BIOTECHNOLOGY MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. Product Type
6.2.2. End-User
6.2.3. By Country
6.3. Asia-Pacific: Country Analysis
6.3.1. China Red Biotechnology Market Outlook.
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. Product Type
6.3.1.2.2. End-User
6.3.2. India Red Biotechnology Market Outlook.
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. Product Type
6.3.2.2.2. End-User
6.3.3. South Korea Red Biotechnology Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. Product Type
6.3.3.2.2. End-User
6.3.4. Japan Red Biotechnology Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. Product Type
6.3.4.2.2. End-User
6.3.5. Australia Red Biotechnology Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. Product Type
6.3.5.2.2. End-User
7. EUROPE RED BIOTECHNOLOGY MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. Product Type
7.2.2. End-User
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. France Red Biotechnology Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. Product Type
7.3.1.2.2. End-User
7.3.2. Germany Red Biotechnology Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. Product Type
7.3.2.2.2. End-User
7.3.3. United Kingdom Red Biotechnology Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. Product Type
7.3.3.2.2. End-User
7.3.4. Italy Red Biotechnology Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. Product Type
7.3.4.2.2. End-User
7.3.5. Spain Red Biotechnology Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. Product Type
7.3.5.2.2. End-User
8. NORTH AMERICA RED BIOTECHNOLOGY MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. Product Type
8.2.2. End-User
8.2.3. By Country
8.3. North America: Country Analysis
8.3.1. United States Red Biotechnology Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. Product Type
8.3.1.2.2. End-User
8.3.2. Mexico Red Biotechnology Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. Product Type
8.3.2.2.2. End-User
8.3.3. Canada Red Biotechnology Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. Product Type
8.3.3.2.2. End-User
9. SOUTH AMERICA RED BIOTECHNOLOGY MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. Product Type
9.2.2. End-User
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Red Biotechnology Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. Product Type
9.3.1.2.2. End-User
9.3.2. Argentina Red Biotechnology Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. Product Type
9.3.2.2.2. End-User
9.3.3. Colombia Red Biotechnology Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. Product Type
9.3.3.2.2. End-User
10. MIDDLE EAST AND AFRICA RED BIOTECHNOLOGY MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. Product Type
10.2.2. End-User
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Red Biotechnology Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. Product Type
10.3.1.2.2. End-User
10.3.2. Saudi Arabia Red Biotechnology Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. Product Type
10.3.2.2.2. End-User
10.3.3. UAE Red Biotechnology Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. Product Type
10.3.3.2.2. End-User
10.3.4. Kuwait Red Biotechnology Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. Product Type
10.3.4.2.2. End-User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Recent Developments
12.2. Mergers & Acquisitions
12.3. Product Developments
13. COMPETITIVE LANDSCAPE
13.1. Business Overview
13.2. Company Snapshot
13.3. Products & Services
13.4. Financials (In case of listed companies)
13.5. Recent Developments
13.6. SWOT Analysis
13.6.1. Pfizer, Inc.
13.6.2. Takeda Pharmaceutical Company Limited
13.6.3. Gilead Sciences
13.6.4. Regeneron Pharmaceuticals, Inc.
13.6.5. F. Hoffmann-La Roche, Ltd.
13.6.6. Bruker
13.6.7. Merck KGaA
13.6.8. Celgene Corporation
13.6.9. Amgen, Inc.
13.6.10. Biogen, Inc.,
14. STRATEGIC RECOMMENDATIONS
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered.
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. RED BIOTECHNOLOGY MARKET OUTLOOK.
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product Type (Diagnostic Reagents, Human Vaccines, Blood Products, Gene Recombinant Drugs and Others)
5.2.2. By Application (Biopharmaceutical Production, Gene Therapy, Genetic Testing, Pharmacogenomics, Drug Discovery, and Others)
5.2.3. By End-User (Pharmaceutical and Biotechnology companies, CMO & CRO, Research Institute and Others)
5.2.4. By Company (2022)
5.2.5. By Region
5.3. Product Market Map
6. ASIA-PACIFIC RED BIOTECHNOLOGY MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. Product Type
6.2.2. End-User
6.2.3. By Country
6.3. Asia-Pacific: Country Analysis
6.3.1. China Red Biotechnology Market Outlook.
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. Product Type
6.3.1.2.2. End-User
6.3.2. India Red Biotechnology Market Outlook.
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. Product Type
6.3.2.2.2. End-User
6.3.3. South Korea Red Biotechnology Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. Product Type
6.3.3.2.2. End-User
6.3.4. Japan Red Biotechnology Market Outlook
6.3.4.1. Market Size & Forecast
6.3.4.1.1. By Value
6.3.4.2. Market Share & Forecast
6.3.4.2.1. Product Type
6.3.4.2.2. End-User
6.3.5. Australia Red Biotechnology Market Outlook
6.3.5.1. Market Size & Forecast
6.3.5.1.1. By Value
6.3.5.2. Market Share & Forecast
6.3.5.2.1. Product Type
6.3.5.2.2. End-User
7. EUROPE RED BIOTECHNOLOGY MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. Product Type
7.2.2. End-User
7.2.3. By Country
7.3. Europe: Country Analysis
7.3.1. France Red Biotechnology Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. Product Type
7.3.1.2.2. End-User
7.3.2. Germany Red Biotechnology Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. Product Type
7.3.2.2.2. End-User
7.3.3. United Kingdom Red Biotechnology Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. Product Type
7.3.3.2.2. End-User
7.3.4. Italy Red Biotechnology Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. Product Type
7.3.4.2.2. End-User
7.3.5. Spain Red Biotechnology Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. Product Type
7.3.5.2.2. End-User
8. NORTH AMERICA RED BIOTECHNOLOGY MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. Product Type
8.2.2. End-User
8.2.3. By Country
8.3. North America: Country Analysis
8.3.1. United States Red Biotechnology Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. Product Type
8.3.1.2.2. End-User
8.3.2. Mexico Red Biotechnology Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. Product Type
8.3.2.2.2. End-User
8.3.3. Canada Red Biotechnology Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. Product Type
8.3.3.2.2. End-User
9. SOUTH AMERICA RED BIOTECHNOLOGY MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. Product Type
9.2.2. End-User
9.2.3. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Red Biotechnology Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. Product Type
9.3.1.2.2. End-User
9.3.2. Argentina Red Biotechnology Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. Product Type
9.3.2.2.2. End-User
9.3.3. Colombia Red Biotechnology Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. Product Type
9.3.3.2.2. End-User
10. MIDDLE EAST AND AFRICA RED BIOTECHNOLOGY MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. Product Type
10.2.2. End-User
10.2.3. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Red Biotechnology Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. Product Type
10.3.1.2.2. End-User
10.3.2. Saudi Arabia Red Biotechnology Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. Product Type
10.3.2.2.2. End-User
10.3.3. UAE Red Biotechnology Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. Product Type
10.3.3.2.2. End-User
10.3.4. Kuwait Red Biotechnology Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. Product Type
10.3.4.2.2. End-User
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Recent Developments
12.2. Mergers & Acquisitions
12.3. Product Developments
13. COMPETITIVE LANDSCAPE
13.1. Business Overview
13.2. Company Snapshot
13.3. Products & Services
13.4. Financials (In case of listed companies)
13.5. Recent Developments
13.6. SWOT Analysis
13.6.1. Pfizer, Inc.
13.6.2. Takeda Pharmaceutical Company Limited
13.6.3. Gilead Sciences
13.6.4. Regeneron Pharmaceuticals, Inc.
13.6.5. F. Hoffmann-La Roche, Ltd.
13.6.6. Bruker
13.6.7. Merck KGaA
13.6.8. Celgene Corporation
13.6.9. Amgen, Inc.
13.6.10. Biogen, Inc.,
14. STRATEGIC RECOMMENDATIONS
